Results 91 to 100 of about 44,893 (265)

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment‐related pathways

British Journal of Haematology, EarlyView.
Selinexor targets molecular pathways critical to myelofibrosis (MF) progenitor cell fitness and demonstrates complementary activity with ruxolitinib, supporting its potential as a novel disease‐modifying therapeutic strategy for MF. Summary Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional ...
Trinayan Kashyap, Andrea A. Ellero, Christopher J. Walker, Marie E. Maloof, Min Lu, Lijuan Xia, Ronald Hoffman, Pietro Taverna   +7 more
wiley   +1 more source

Diagnosis and management of neutropenia in adults: Expert guidance

British Journal of Haematology, EarlyView.
Severe neutropenia can result from decreased production of neutrophil precursors in the bone marrow, as in the case of severe congenital neutropenia, or from increased utilization of neutrophils or their accelerated destruction as for drug‐induced neutropenia or autoimmune neutropenia. Severe chronic neutropenia increases susceptibility to bacterial or
Karl Welte, Cornelia Zeidler, Julia Skokowa, Sabine Mellor‐Heineke, Audrey Anna Bolyard, David Dale   +5 more
wiley   +1 more source

Outcomes of patients with de novo and secondary acute myeloid leukaemia treated with front‐line hypomethylating agents and venetoclax: A retrospective Italian study

British Journal of Haematology, EarlyView.
Ilaria Tanasi, Edoardo Tamellini, Elena Marchetti, Eleonora De Bellis, Cristina Ancora, Francesco Angotzi, Davide Facchinelli, Francesca Capraro, Giulia Battaglia, Alessandra Sperotto, Michele Gottardi, Matteo Leoncin, Mauro Krampera, Mario Tiribelli, Carmela Gurrieri   +14 more
wiley   +1 more source

Real‐world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS‐like tyrosine kinase 3 (FLT3)‐mutated relapsed/refractory acute myeloid leukaemia: A UK single‐centre experience

British Journal of Haematology, EarlyView.
In FMS‐like tyrosine kinase 3 (FLT3)‐mutated relapsed/refractory acute myeloid leukaemia, gilteritinib, azacitidine and venetoclax is an effective salvage option with an ORR of 100% (mCRc [MLFS + CRc] 93%). Sixty‐two per cent of patients treated with intention‐to‐transplant proceeded to allogeneic haematopoietic stem cell transplant, of whom 50% remain
Wei Yee Chan, Hannah Al‐Yousuf, Ho Pui Jeff Lam, Sarah Leong, Jiexin Zheng, Richard Burt, Andrew J. Wilson, Ke Xu, Kate Stringaris, Samah Alimam, Kavita Raj, Rajeev Gupta, Panagiotis Kottaridis, Anish Tailor, Rebecca Burgoyne, Marc R. Mansour, Asim Khwaja, Rob Sellar, Elspeth M. Payne, Jenny O'Nions   +19 more
wiley   +1 more source

Cytogenetic finding of simultaneous inversion of chromosome 14 and tetrasomy 8 in a Pediatric B-Lymphoblastic Leukemia-a case report

Molecular Cytogenetics
Background Clonal cytogenetic abnormalities in B-lymphoblastic leukemia (B-ALL) include structural and numerical chromosomal alterations, where numerical are the most common aberrations.
Kiran Sachwani, Rehab Pasha, Bushra Kaleem, Neelum Mansoor   +3 more
doaj   +1 more source

A proposed refined definition of acute myeloid leukaemia patients ineligible for intensive therapy: The Integrated Comorbidity–ECOG–Age criteria

British Journal of Haematology, EarlyView.
Daniel Weidl, Myrto Boukovala, Doris Glaser, Bettina Barthel, Lars Bullinger, Michael Heuser   +5 more
wiley   +1 more source

Socioeconomic inequality in treatment of acute myeloid leukaemia (AML) in England, 2015–2022: A population‐based study

British Journal of Haematology, EarlyView.
Summary The socioeconomic inequality in acute myeloid leukaemia (AML) survival may be driven by differential access to intensive chemotherapy (ICT). We aimed to quantify socioeconomic inequality in the receipt of ICT among patients with AML in England and identify its key drivers. We evaluated 10 495 patients with de novo AML identified in the national
Koki Shimizu, Mari Kajiwara Saito, Camille Maringe, Yasushi Miyazaki, Bernard Rachet   +4 more
wiley   +1 more source

Real‐world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high‐risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry

British Journal of Haematology, EarlyView.
Kenneth J. C. Lim, Elham Ashrafi, Cameron Wellard, Elizabeth M. Moore, Betty Gration, Bradley Augustson, Peter Mollee, Jennifer Zhang, Nicole Wong Doo, Karen Dun, Rachel Cooke, Sabine Ringkowski, Adam Bryant, Georgia McCaughan, Erica Wood, Zoe McQuilten, P. Joy Ho, Hang Quach, Andrew Spencer   +18 more
wiley   +1 more source

Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma

British Journal of Haematology, EarlyView.
In patients with lenalidomide‐refractory multiple myeloma from the BOSTON trial subgroup analysis,1 selinexor (SEL) dose reduction versus full dosing substantially improved efficacy outcomes, including higher overall response rate (74.3% vs. 55.6%), deeper responses (≥ very good partial response: 48.6% vs.
Muhamed Baljevic
wiley   +1 more source

Safety profile of chimeric antigen receptor T‐cell therapy in relapsed/refractory multiple myeloma: A systematic review and meta‐analysis of proportions from clinical trials

British Journal of Haematology, EarlyView.
Charalampos Filippatos, Ioannis Ntanasis‐Stathopoulos, Areti Voulomenou, Panagiotis Malandrakis, Efstathios Kastritis, Maria Gavriatopoulou, Meletios‐Athanasios Dimopoulos, Evangelos Terpos   +7 more
wiley   +1 more source